Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente Report issue

Academic/Hospital Phase 2 Phase 4

Organization Overview

First Clinical Trial
2007
NCT01949571
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente

Active Ingredients

Drugs in Phase 4 Trials (1)

melatonin (1 trial)

Drugs in Phase 2 Trials (1)

mirtazapine (remeron) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Depression (Phase 2)

Substance-Related Disorders (Phase 2)

Substance Withdrawal Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 2